Supportive Medicines Phase 5a - Propofol 1g/50ml Emulsion for Infusion

CPV: Pharmaceutical products

Procedure method

Award procedure without prior publication of a call for competition

Legal basis

CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)

Procurement category

Goods

Notice status

Awarded without competition

Procurement threshold

Unspecified in notice

Regulatory regime

Standard

Commercial structure

Stand-alone contract (no framework)

Competition type

Direct award (no call for competition)

GPA / WTO covered

Yes (GPA)

Recurring procurement

Unspecified in notice

First published

17 Feb 2022, 16:52 GMT

Last source update

17 Feb 2022, 16:52 GMT

Authority reference

CM-EMI-21-C57450

FTS notice number

2022/S 000-004568

Classification (CPV)

Pharmaceutical products

Delivery area

UK

Official registry OCID

ocds-h6vhtk-031874 Find a Tender

Why no open competition

Extreme urgency brought about by events unforeseeable for the contracting authority/entity and in accordance with the strict conditions stated in the directive

Published justification

The Coronavirus disease (Covid-19) is a serious infectious respiratory disease and its consequences pose a risk to life. The Covid-19 pandemic supportive medicines stockpile was designed as a ‘one off’ build to target volumes of a defined range of critical products used within the intensive treatment units and end of life environments. However, developments in Winter 2021 around the Omicron variant and heightened risk perception within Government prompted activation of the ‘Challenging Winter Peak’ Scenario at very short notice, resulting in an urgent requirement to procure additional volumes of some critical products to avoid their complete stockout in the month of January 2022. The global stock of Propofol is limited and there are many buyers competing for the same supplies. It is imperative that security of supply is maintained for public health purposes. Due to the short delivery timeframe required to mitigate a complete stockout, the authority did not have sufficient time to comply with the standard open procedure time scales for this procurement. Accordingly, the Authority used the negotiated procedure without prior publication – Regulation 32(2)(c) – Extreme Urgency Route (i.e. direct award) permitted under the Public Contract Regulations 2015 (as amended) to conduct this procurement

Publisher note: Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate cost per vial. This will (i) commercially prejudice the contracting authority in its commercial dealings with other suppliers; and (ii) impact fair competition between suppliers.<br/><br/>The Contract is for the benefit of the Authority and NHS bodies along with any other non-NHS bodies which are necessary for the delivery of Products to NHS bodies, local authorities, other government departments and their executive agencies or non-departmental public bodies charged with the delivery of healthcare or health related services in the United Kingdom, Crown Dependencies and British Overseas Territories including, without limitation, the National Assembly for Wales, the Northern Ireland Assembly, and Scottish Ministers. The resulting Products delivered against the contract may be made available to the UK devolved administrations, Crown Dependencies and British Overseas Territories .

• B. Braun Medical LimitedAwarded supplier2296559 Thorncliffe Park, Sheffield, Sheffield, Yorkshire & Humber, S35 2PW

No document links were published on the notice.